wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4
Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4
Emerging molecularly targeted therapies in castration refractory prostate cancer
P2860
Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4
BestRank
Statement
http://www.wikidata.org/entity/statement/Q21284745-AD1FFD6C-9425-4C4B-877E-68E4F4009DE4
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8df8cb38e07a40b808c0b7735fbb38f18e4cdb0f
P2860
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.